Agnieszka Boesen

Array ( [id] => 14833481 [patent_doc_number] => 20190275141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => RSV IMMUNIZATION REGIMEN [patent_app_type] => utility [patent_app_number] => 16/423507 [patent_app_country] => US [patent_app_date] => 2019-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34006 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16423507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15869067 [patent_doc_number] => 20200141937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/422211 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946693 [patent_doc_number] => 20210205384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => ECHO-7 ONCOLYTIC VIRUS FOR USE IN THE TREARMENT OF UVEAL MELANOMA [patent_app_type] => utility [patent_app_number] => 17/057230 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990240 [patent_doc_number] => 20210228660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => USE OF PROTEASOME INHIBITOR AND ALPHAVIRUS IN PREPARATION OF ANTI-TUMOR MEDICAMENT [patent_app_type] => utility [patent_app_number] => 17/057489 [patent_app_country] => US [patent_app_date] => 2019-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806165 [patent_doc_number] => 20210128718 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => TREATMENT AND PREVENTION OF HOUSE DUST MITE ALLERGIES [patent_app_type] => utility [patent_app_number] => 17/055817 [patent_app_country] => US [patent_app_date] => 2019-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227217 [patent_doc_number] => 12415860 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Binding moiety for conditional activation of immunoglobulin molecules [patent_app_type] => utility [patent_app_number] => 17/055096 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 64 [patent_no_of_words] => 25158 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548177 [patent_doc_number] => 20220119518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => USE FOR PREVENTING AND TREATING MYELOID-DERIVED SUPPRESSOR CELL-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/052591 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227217 [patent_doc_number] => 12415860 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Binding moiety for conditional activation of immunoglobulin molecules [patent_app_type] => utility [patent_app_number] => 17/055096 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 64 [patent_no_of_words] => 25158 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18427651 [patent_doc_number] => 11672852 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Universal mammalian influenza vaccine [patent_app_type] => utility [patent_app_number] => 16/400817 [patent_app_country] => US [patent_app_date] => 2019-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 26 [patent_no_of_words] => 17606 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16400817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035725 [patent_doc_number] => 20190328867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => Specific Binding Agents to Varicella-Zoster Virus and Uses Related Thereto [patent_app_type] => utility [patent_app_number] => 16/394360 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16394360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16712259 [patent_doc_number] => 20210079406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => AAV VECTORS ENCODING CLARIN-1 OR GJB2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/046487 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19679 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14652749 [patent_doc_number] => 20190233503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => METHOD OF MANUFACTURING PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION III AND NON-PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION IV [patent_app_type] => utility [patent_app_number] => 16/379559 [patent_app_country] => US [patent_app_date] => 2019-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16379559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17306316 [patent_doc_number] => 11207399 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Influenza virus mutants and uses therefor [patent_app_type] => utility [patent_app_number] => 16/368315 [patent_app_country] => US [patent_app_date] => 2019-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 77 [patent_no_of_words] => 29429 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16368315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806162 [patent_doc_number] => 20210128715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING HEMAGGLUTININ [patent_app_type] => utility [patent_app_number] => 17/041784 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 376 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17489331 [patent_doc_number] => 11278612 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-22 [patent_title] => Multivalent influenza nanoparticle vaccines [patent_app_type] => utility [patent_app_number] => 16/357876 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 14661 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16357876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868671 [patent_doc_number] => 20190284577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => EHV WITH INACTIVATED UL18 AND/OR UL8 [patent_app_type] => utility [patent_app_number] => 16/358519 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16058499 [patent_doc_number] => 10688173 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines [patent_app_type] => utility [patent_app_number] => 16/287559 [patent_app_country] => US [patent_app_date] => 2019-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 15 [patent_no_of_words] => 19843 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16287559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19503268 [patent_doc_number] => 12114664 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => None [patent_app_type] => utility [patent_app_number] => 17/043847 [patent_app_country] => US [patent_app_date] => 2019-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6437 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14338941 [patent_doc_number] => 20190151443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => Nucleic Acid Molecule Encoding Hepatitis B Virus Core Protein And Vaccine Comprising The Same [patent_app_type] => utility [patent_app_number] => 16/267454 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060135 [patent_doc_number] => 11104722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Immunogenetic restriction on elicitation of antibodies [patent_app_type] => utility [patent_app_number] => 16/259209 [patent_app_country] => US [patent_app_date] => 2019-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 20 [patent_no_of_words] => 31913 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16259209 [rel_patent_id] =>[rel_patent_doc_number] =>)